FDA Approves Eli Lilly's Foundayo (Orforglipron): The First Small-Molecule Oral GLP-1 Pill

On April 1, 2026, the FDA approved Eli Lilly's Foundayo (orforglipron) for chronic weight management in adults with obesity, or who are overweight with at least one weight-related condition. It's a once-daily pill, and Lilly and outside coverage have both described it as the first GLP-1 receptor agonist approved as a small molecule rather than a peptide.

Rybelsus, the existing oral semaglutide tablet, is a peptide that requires a specific absorption enhancer and strict dosing rules — taken on an empty stomach with a small sip of water, then nothing else for at least 30 minutes. Orforglipron is a small-molecule compound, which Lilly says can be taken at any time of day without food or water restrictions, and which is generally simpler and cheaper to manufacture at scale than a peptide.

In a trial enrolling more than 3,000 adults with obesity, participants on the highest studied dose (36 mg) lost an average of 11.2% of body weight — roughly 25 pounds — over more than 16 months, compared with 2.1% in the placebo group. As with any trial result, that's a population average, not a prediction for any individual.

Lilly made Foundayo available through its LillyDirect telehealth and pharmacy platform starting April 6, with broader availability through retail pharmacies and other telehealth providers following shortly after.

Longer-term safety and durability data, insurance formulary coverage decisions, and head-to-head comparisons against injectable GLP-1 drugs are all still developing. This article describes the approval as reported; check the FDA's own label database for the current, authoritative prescribing information.